Last updated: February 27, 2026
What is NDC 59651-0422?
NDC 59651-0422 is a prescription drug distributed by Sandoz Inc. It is marketed as Bleomycin Sulfate Injection, a chemotherapeutic agent used primarily in treating Hodgkin's lymphoma, non-Hodgkin's lymphoma, and germ cell tumors.
Market Size and Key Drivers
Current Market Overview
- The global chemotherapy drugs market was valued at approximately USD 24 billion in 2022.
- Bleomycin's share within this segment remains below 2%, given its narrow oncology application scope.
- Sandoz's generic version competes with branded formulations, including products from Merck and Bristol-Myers Squibb.
Sales Volume
- Estimated global annual sales for Bleomycin sulfate formulations hover around USD 200 million.
- North American markets dominate, accounting for approximately 60% of sales.
- The product’s uptake depends on hospital formularies, oncologist prescribing patterns, and regulatory approvals.
Drivers
- Expansion of chemotherapy protocols.
- Patent expirations leading to increased generic availability.
- Growing cancer incidence rates globally, especially in aging populations.
- Healthcare policies favoring cost-effective therapeutics.
Barriers
- Limited indications restrict overall market volume.
- Safety concerns over pulmonary toxicity limit use cases.
- Competition from other chemotherapeutic agents and targeted therapies.
Price Analysis and Projection
Current Pricing Landscape
- Wholesale acquisition cost (WAC) for NDC 59651-0422 averages USD 150 per vial (varies by supplier and quantity).
- Retail prices in hospital settings are approximately USD 200–USD 250 per vial.
- Contract pricing contracts and bulk purchasing arrangements often reduce effective costs to USD 100–USD 125 per vial.
Price Trends (Recent 3 Years)
| Year |
Average Price per Vial (USD) |
Notes |
| 2020 |
180 |
Slight decrease post-pandemic pricing adjustments |
| 2021 |
170 |
Market stabilization, pricing consolidation |
| 2022 |
150 |
Cost pressures, increased competition |
Projected Price Movements (Next 3 Years)
- Prices are expected to decline marginally due to increased generic penetration.
- WAC may decrease by approximately 10% annually, reaching USD 130–USD 140 per vial by 2025.
- Discounted prices for hospital contracts could drop further to USD 90–USD 100 per vial.
Factors Influencing Future Prices
- Entry of additional generics or biosimilars could intensify price competition.
- Regulatory changes, such as permit expansions or restrictions, impact supply and demand.
- Cost of raw materials, notably cytotoxic compounds, influences manufacturing costs.
- Reimbursement policies affect hospital and healthcare provider purchase behaviors.
Market Outlook and Opportunities
Growth Opportunities
- Developing combination regimens with novel agents.
- Expanding into emerging markets where chemotherapy access expands.
- Positioning as a cost-effective alternative in hospitals sensitive to drug expenditure.
Risks
- Slow adoption due to safety concerns.
- Regulatory hurdles delaying generic market entry.
- Competition from targeted therapies that replace traditional chemotherapeutics.
Conclusion
NDC 59651-0422 operates within a niche but stable segment in oncology pharmaceuticals. The market dynamics favor moderate growth driven by increasing cancer prevalence and broader acceptance of generics. Price projections indicate a downward trend driven by competition and market saturation, with potential stabilization at lower price points within the next three years.
Key Takeaways
- The current global sales for Bleomycin Sulfate Injection are approximately USD 200 million.
- Prices are declining gradually, with projections pointing to a 10% annual decrease over the next three years.
- Market expansion relies on generic entry, pricing strategies, and evolving treatment protocols.
- Barriers include safety concerns, limited indications, and competition from newer therapies.
- Opportunities exist in emerging markets and combination therapy development.
FAQs
1. What factors influence the price of Bleomycin Sulfate Injection?
Pricing is affected by generic competition, raw material costs, regulatory changes, hospital procurement strategies, and reimbursement policies.
2. How does the competition impact the market for NDC 59651-0422?
Increased generic availability and biosimilars tend to drive prices downward and increase market share, especially in cost-sensitive healthcare systems.
3. What is the typical market entry timeline for new generics of Bleomycin?
Entry timelines vary; regulatory approval can take 1–2 years post-ANDA submission, with market penetration depending on manufacturing capacity and distribution channels.
4. Are there any recent regulatory changes affecting Bleomycin pricing?
No significant recent regulatory changes have directly impacted pricing, but ongoing oncology standards and safety requirements influence pricing and market dynamics.
5. How does the current market size compare to other chemotherapeutic agents?
Bleomycin accounts for a small fraction of the overall chemotherapy market but remains relevant in specific treatment protocols.
References
- Statista. (2023). Oncology drugs market size. https://www.statista.com
- IQVIA. (2022). Global Oncology Market Data. Retrieved from IQVIA reports.
- U.S. Food and Drug Administration. (2022). Regulatory guidelines for chemotherapy drugs.
- IMS Health. (2022). Price trends in oncology therapeutics.
